Genus PLC 2025 AR2
The report highlights Genus plc's strong performance in FY25, with Group revenue increasing by 1% to £672.8m and statutory profit before tax rising to £28.5m. A major milestone was achieved with the US FDA regulatory approval for the PRRSv-resistant pig (PRP) gene edit in April 2025. The company also successfully completed Phase 2 of its ABS Value Acceleration Programme, delivering £8.0m of benefit in the year. Additionally, Genus completed life cycle assessments in Europe and for NuEra Genetics, demonstrating significant greenhouse gas emissions reductions compared to industry averages.
Company: Genus PLC
Sector: Agriculture, forestry & fishing
Country: United Kingdom
Year: 2025
Type: AR2
Pages: 221
Back to company
Genus PLC
Annual Report
The report highlights Genus plc's strong performance in FY25, with Group revenue increasing by 1% to £672.8m and statutory profit before tax rising to £28.5m. A major milestone was achieved with the US FDA regulatory approval for the PRRSv-resistant pig (PRP) gene edit in April 2025. The company also successfully completed Phase 2 of its ABS Value Acceleration Programme, delivering £8.0m of benefit in the year. Additionally, Genus completed life cycle assessments in Europe and for NuEra Genetics, demonstrating significant greenhouse gas emissions reductions compared to industry averages.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jul 1, 2024 - Jun 30, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Women on Board
Women in Management
Net Zero Target
Employees